13/03/2019 11:05:00

Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit

SAN FRANCISCO, March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Derek Small, Assembly’s President and Chief Executive Officer will participate in the Jefferies 2019 HBV Summit on Monday, March 18, 2019 in New York.

A webcast of the HBV Summit will be available in the Events and Presentations section of the Company’s website at www.assemblybio.com.

           

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live synthetic biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.

Contacts

Assembly Biosciences, Inc.

Investors:

Lauren Glaser

(415) 521-3828

lglaser@assemblybio.com 

ASMBlogo.jpg

Related content
22 Apr - 
Development Veteran Steven J. Knox Joins Assembly Biosc..
15 Apr - 
Factors of Influence in 2019, Key Indicators and Opport..
13 Apr - 
Assembly Biosciences Presents Interim Data from Two Pha..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
With $3M Dividend in 2019, Nonprofit Insurer's Dividends Paid to Members Top $44.1M
2
Extendicare Announces Nomination of Two New Directors and Agreement with Sandpiper Group
3
Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States
4
PDF Solutions® Announces First Fiscal Quarter Financial Results Release Date
5
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Nokia Corporation (NOK) and Encourages NOK Investors to Contact the Firm

Related stock quotes

Assembly Biosciences Inc 15.21 -2.2% Stock price decreasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 April 2019 23:42:19
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB6 - 2019-04-24 00:42:19 - 2019-04-23 23:42:19 - 1000 - Website: OKAY